Advancements in NSCLC Treatment: Mandatory EGFR Testing for Stage III Patients
Recent recommendations from experts suggest that all stage III non-small cell lung cancer (NSCLC) patients should undergo EGFR testing following chemoradiotherapy. This new protocol aims to improve treatment outcomes and personalize care for this patient population.
Key Findings from the LAURA Trial
The LAURA trial, a groundbreaking study in the field of NSCLC treatment, revealed significant advancements in patient outcomes. Patients with unresectable stage III NSCLC who did not experience disease progression post-chemoradiotherapy saw a remarkable increase in median progression-free survival (PFS) when treated with osimertinib, an EGFR inhibitor. The PFS increased from 5.6 months with a placebo to an impressive 39.1 months with osimertinib, showcasing a sevenfold improvement in outcomes.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
